Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies

a systematic review of randomized controlled trials

Authors

  • Jerry Lorren Dominic General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States https://orcid.org/0000-0003-0755-3153
  • Amudhan Kannan Jawaharlal Institute of Postgraduate Medical EducationaAnd Research (JIPMER), Puducherry, India https://orcid.org/0000-0002-7289-7035
  • Anjli Tara General Surgery, California Institute of Behavioral Neurosciences and Psychology, Fairfield, California, United States https://orcid.org/0000-0002-0425-576X
  • Abdul Rub Hakim Mohammed Emergency Medicine, The George Washington University - Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, India https://orcid.org/0000-0001-9158-503X
  • Myat Win General Surgery, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom https://orcid.org/0000-0003-4439-1907
  • Arseni Khorochkov General Surgery, California Institute of Behavioral Neurosciences and Psychology, Fairfield, California, United States https://orcid.org/0000-0002-4347-4455
  • Waleed Sultan General Surgery, Halifax Health Medical Center, Daytona Beach, Florida, United States https://orcid.org/0000-0001-5221-2820
  • Asma Ahmed General Surgery, University of Missouri - Kansas City, Missouri, United States https://orcid.org/0000-0002-4914-3155
  • Ketan Kantamaneni General Surgery, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Gannavaram, Andhra Pradesh, India https://orcid.org/0000-0002-6174-5001
  • Michael W. Syzmanski General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States https://orcid.org/0000-0002-7685-5983
  • Rajbir Singh General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States https://orcid.org/0000-0001-7020-0145
  • Raul A. Marquez Orthopedic Surgery, Cornerstone Regional Hospital/South Texas Health System, Edinburg, Texas, United States https://orcid.org/0000-0002-7100-0337
  • Armand Asarian General Surgery, The Brooklyn Hospital Center, Brooklyn, New York, United States https://orcid.org/0000-0002-4749-4226
  • Pragatheeshwar Thirunavukarasu Director of Surgical Oncology, Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States; Adjunct Clinical Assistant Professor of Surgery, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States. Tel.: +1 910-987-5706; E-mail: pragmd@outlook.com https://orcid.org/0000-0002-4714-5907
  • George Keckeisen Director of General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States https://orcid.org/0000-0002-6885-557X

DOI:

https://doi.org/10.17179/excli2021-4108

Keywords:

hyperthermic intraperitoneal chemotherapy, peritoneal neoplasms, gastrointestinal neoplasm, gastric neoplasm, colorectal neoplasm, mortality

Abstract

Peritoneal metastasis is associated with poor prognosis, with studies in the literature reporting the survival of peritoneal metastasis without treatment to be three to six months. Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown positive outcomes by improving the prognosis in patients with gastrointestinal malignancies. This systematic review of randomized controlled trials was done to determine the prophylactic role of hyperthermic intraperitoneal chemotherapy in preventing and controlling peritoneal metastasis gastrointestinal origin. Randomized controlled trials published between January 2019 to June 2021 were included. The databases used were MEDLINE (PubMed), EMBASE (Ovid), and the Cochrane library. Cochrane handbook for systematic review of intervention was used to assess the risk of bias in included trials. The results were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A total of five trials met the inclusion criteria. Two studies were on patients with gastric cancer, and the other three studies were on patients with colorectal cancer. HIPEC was given to a total of 116 gastric cancer patients and 308 colorectal cancer patients. In all the included studies on patients with gastric cancer, the peritoneal recurrence-free survival was significantly higher in the group that received HIPEC. There was no significant improvement in peritoneal-free survival in patients with colorectal cancer who received HIPEC. HIPEC appears to be effective in preventing peritoneal metastasis in patients with locally advanced gastric cancer without minimal postoperative complications. However, in patients with advanced colorectal malignancy, HIPEC does not seem to play a crucial role in preventing and controlling peritoneal metastasis.

Published

2021-08-19

How to Cite

Dominic, J. L., Kannan, A., Tara, A., Hakim Mohammed, A. R. ., Win, M. ., Khorochkov, A. ., … Keckeisen, G. (2021). Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies: a systematic review of randomized controlled trials. EXCLI Journal, 20, 1328–1345. https://doi.org/10.17179/excli2021-4108

Issue

Section

Review articles

Most read articles by the same author(s)